Shots:
- Veralox has signed an exclusive agreement to acquire Nudge Therapeutics & its preclinical cyclic AMP-GMP (cGAS) inhibitors. The financial terms were undisclosed
- As per the terms, Veralox will resume the development of acquired candidates & initiate acquisition upon achievement of downstream milestones
- In addition, Veralox is developing VLX-1005 (12-LOX inhibitor) for thrombosis linked to heparin-induced thrombocytopenia (HIT) that showed favourable safety & tolerability in 2 P-I studies involving 96 healthy subjects. Its P-II (VLX-1005-003) trial is now enrolling patients at 14 sites & expected to achieve clinical PoC in 2025
Ref: Prnewswire | Image: Veralox Therapeutics
Related News:- Transcarent to Acquire Accolade for ~$621M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
